X4 Pharmaceuticals, Inc. – NASDAQ:XFOR
Founder-led company
X4 Pharmaceuticals stock price today
$2.98
+2.17
+270.71%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
X4 Pharmaceuticals stock price monthly change
+14.51%
month
X4 Pharmaceuticals stock price quarterly change
+14.51%
quarter
X4 Pharmaceuticals stock price yearly change
-7.12%
year
X4 Pharmaceuticals key metrics
Market Cap | 102.92M |
Enterprise value | 12.43M |
P/E | -0.62 |
EV/Sales | N/A |
EV/EBITDA | -0.13 |
Price/Sales | N/A |
Price/Book | 1.29 |
PEG ratio | -0.01 |
EPS | -0.98 |
Revenue | N/A |
EBITDA | -114.54M |
Income | -165.49M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeX4 Pharmaceuticals stock price history
X4 Pharmaceuticals stock forecast
X4 Pharmaceuticals financial statements
| Mar 2023 | 0 | -55.71M | |
|---|---|---|---|
| Jun 2023 | 0 | -55.71M | |
| Sep 2023 | 0 | -2.30M | |
| Mar 2024 | 0 | -51.76M |
| Mar 2024 | 0 | -51.76M | |
|---|---|---|---|
| Sep 2025 | 14.15M | -25.83M | -182.61% |
| Oct 2025 | 7.2M | -27.99M | -388.87% |
| Dec 2025 | 9.13M | -24.66M | -270.05% |
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 173399000 | 105.86M | 61.05% |
|---|---|---|---|
| Jun 2023 | 173399000 | 105.86M | 61.05% |
| Sep 2023 | 173293000 | 105.69M | 60.99% |
| Mar 2024 | 112182000 | 111.14M | 99.08% |
| Mar 2023 | -21.42M | -4.88M | 69.33M |
|---|---|---|---|
| Jun 2023 | -21.42M | -4.88M | 69.33M |
| Sep 2023 | -20.82M | -5.15M | 21.20M |
| Mar 2024 | -33.59M | -5.32M | 0 |
X4 Pharmaceuticals alternative data
| Aug 2023 | 40 |
|---|---|
| Sep 2023 | 40 |
| Oct 2023 | 40 |
| Nov 2023 | 40 |
| Dec 2023 | 86 |
| Jan 2024 | 86 |
| Feb 2024 | 86 |
| Mar 2024 | 93 |
| Apr 2024 | 93 |
| May 2024 | 93 |
| Jun 2024 | 116 |
| Jul 2024 | 116 |
X4 Pharmaceuticals other data
10.95%
-61.89%
of XFOR is owned by hedge funds
34
-17
6.95M
-53.65M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 53886 |
| Mar 2024 | 0 | 131822 |
| Sep 2024 | 0 | 2642 |
| Oct 2024 | 0 | 657720 |
| Nov 2024 | 0 | 31897 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | RAGAN PAULA director, officer.. | Common Stock | 31,897 | $0.4 | $12,599 | ||
Sale | RAGAN PAULA director, officer.. | Common Stock | 31,897 | $0.56 | $17,926 | ||
Sale | MOSTAFA ADAM S. officer: Chief Fi.. | Common Stock | 230,645 | $0.55 | $126,855 | ||
Sale | BALDRY MARK officer: Chief Commercial Officer | Common Stock | 11,127 | $0.59 | $6,509 | ||
Sale | RAGAN PAULA director, officer.. | Common Stock | 239,436 | $0.55 | $131,450 | ||
Sale | DIBIASE MARY officer: Chief Operating Officer | Common Stock | 67,695 | $0.57 | $38,315 | ||
Sale | TAVERAS ARTHUR officer: Chief Scientific Officer | Common Stock | 76,920 | $0.56 | $43,306 | ||
Sale | DIBIASE MARY officer: Chief Operating Officer | Common Stock | 2,642 | $0.66 | $1,738 | ||
Sale | TAVERAS ARTHUR officer: Chief Scientific Officer | Common Stock | 14,235 | $0.88 | $12,555 | ||
Sale | RAGAN PAULA director, officer.. | Common Stock | 49,678 | $0.88 | $43,866 |
| Patent |
|---|
Application Filling date: 14 Dec 2021 Issue date: 18 Aug 2022 |
Grant Utility: Methods for treating cancer Filling date: 10 Apr 2017 Issue date: 24 May 2022 |
Grant Utility: CXCR4 inhibitors and uses thereof Filling date: 21 Jun 2017 Issue date: 17 May 2022 |
Grant Utility: CXCR4 inhibitors and uses thereof Filling date: 27 Jul 2020 Issue date: 19 Apr 2022 |
Application Filling date: 15 Jul 2021 Issue date: 20 Jan 2022 |
Application Filling date: 25 Jun 2021 Issue date: 13 Jan 2022 |
Grant Filling date: 28 Feb 2020 Issue date: 11 Jan 2022 |
Application Filling date: 22 Mar 2021 Issue date: 25 Nov 2021 |
Application Filling date: 6 Nov 2018 Issue date: 11 Nov 2021 |
Grant Filling date: 5 Dec 2019 Issue date: 29 Jun 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside
X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying
X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market
X4 Pharmaceuticals: Mavorixafor Could Change Chronic Neutropenic Treatment Landscape
X4 Pharmaceuticals: Chronic Neutropenia Might Finally Have Met Its Match
X4 Pharmaceuticals: Upcoming Catalysts
X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
-
What's the price of X4 Pharmaceuticals stock today?
One share of X4 Pharmaceuticals stock can currently be purchased for approximately $2.98.
-
When is X4 Pharmaceuticals's next earnings date?
Unfortunately, X4 Pharmaceuticals's (XFOR) next earnings date is currently unknown.
-
Does X4 Pharmaceuticals pay dividends?
No, X4 Pharmaceuticals does not pay dividends.
-
How much money does X4 Pharmaceuticals make?
X4 Pharmaceuticals has a market capitalization of 102.92M.
-
What is X4 Pharmaceuticals's stock symbol?
X4 Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "XFOR".
-
What is X4 Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of X4 Pharmaceuticals?
Shares of X4 Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are X4 Pharmaceuticals's key executives?
X4 Pharmaceuticals's management team includes the following people:
- Dr. Paula Ragan Ph.D. Founder, Chief Executive Officer, Pres, Sec. & Director(age: 55, pay: $551,570)
- Mr. Derek M. Meisner Esq., J.D. Chief Legal Officer & Corporation Sec.(age: 54, pay: $479,460)
- Mr. Adam S. Mostafa Chief Financial Officer, Treasurer & Assistant Sec.(age: 45, pay: $400,560)
-
Is X4 Pharmaceuticals founder-led company?
Yes, X4 Pharmaceuticals is a company led by its founder Dr. Paula Ragan Ph.D..
-
How many employees does X4 Pharmaceuticals have?
As Jul 2024, X4 Pharmaceuticals employs 116 workers, which is 25% more then previous quarter.
-
When X4 Pharmaceuticals went public?
X4 Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 16 Nov 2017.
-
What is X4 Pharmaceuticals's official website?
The official website for X4 Pharmaceuticals is x4pharma.com.
-
Where are X4 Pharmaceuticals's headquarters?
X4 Pharmaceuticals is headquartered at 61 North Beacon Street, Boston, MA.
-
How can i contact X4 Pharmaceuticals?
X4 Pharmaceuticals's mailing address is 61 North Beacon Street, Boston, MA and company can be reached via phone at 857 529 8300.
X4 Pharmaceuticals company profile:
X4 Pharmaceuticals, Inc.
x4pharma.comExchange:
NASDAQ
Full time employees:
127
Industry:
Biotechnology
Sector:
Healthcare
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
61 North Beacon Street
Boston, MA 02134
Boston, MA 02134
CIK: 0001501697
ISIN: US98420X1037
CUSIP: 98420X103
